Table 2 Clinical indicators estimated, in the first year of follow-up, for patients newly taken-in-care with personality disorders treated by local DMHs, stratified for area (Lombardy, Emilia Romagna and Lazio Regions and Province of Palermo) and in the whole sample. QUADIM-MAP projects, Italy, 2015–2016

Age-, gender-standardized treated prevalence rate (x 10,000)

3.4

5.5

2.8

4.7

4.1

ACCESSIBILITY AND APPROPRIATENESS OF MENTAL HEALTH CARE

1

Patients with at least one outpatient contact in CMHCs or DCs

82.0%

96.7%

84.0%

98.0%

90.9%

98

2

Median number of outpatient contacts in CMHCs (per PY)

8.0

8.0

7.0

6.0

7.2

73

3

Patients with at least one psychiatric visit

70.2%

85.9%

71.7%

69.6%

74.2%

97

4

Median number of outpatient psychiatric visits (per PY)

4.0

4.0

3.0

3.0

3.6

81

5

Patients with at least one standardized assessment using tests

12.2%

7.7%

9.4%

11.3%

10.6%

98

6

Median number of standardized assessments using tests (per PY)

1.0

2.0

1.0

1.0

1.0

0

7

Patients treated with at least one psychosocial intervention in CMHCs

53.9%

50.2%

65.1%

58.5%

54.9%

83

8

Median number of psychosocial interventions in CMHCs (per PY)

5.0

3.0

4.0

4.0

4.0

71

9

Patients treated with at least one psychoeducation session ‡

3.4%

3.8%

4.7%

3.6%

0

10

Median number of psychoeducation sessions (per PY)‡

3.0

3.0

1.0

2.9

0

11

Patients treated with at least one psychotherapy session

37.9%

19.9%

37.7%

40.5%

34.0%

99

12

Median number of psychotherapy sessions (per PY)

5.0

5.0

3.5

6.0

5.1

14

13

Median number of interventions specifically addressed to patients’ family members (per PY)

2.0

2.0

2.0

1.0

1.7

83

14

Patients treated with antipsychotic agents

27.2%

34.2%

21.7%

21.0%

26.8%

90

15

Patients treated with Mood Stabilizers

30.2%

36.0%

31.1%

21.4%

29.0%

92

Patients treated with Lithium

1.9%

3.4%

1.9%

1.0%

2.0%

70

Patients treated with Valproic acid, Carbamazepine

13.5%

13.1%

24.5%

12.3%

13.5%

62

16

Patients treated with Antidepressant agents

38.4%

43.7%

21.7%

22.8%

34.1%

97

17

Patients with at least one admission in residential facilities

13.1%

13.1%

0.9%

8.3%

11.1%

97

18

Median number of days spent in residential facilities (per PY)

15.0

27.0

365.2

51.0

110.7

99

19

Patients with at least one admission in GHPW

12.6%

13.6%

10.4%

5.6%

10.6%

92

20

Median number of days spent in GHPW (per PY)

14.0

12.0

25.0

11.0

12.8

0

21

Admissions with a length of stay in GHPW higher than 30 days

3.5%

5.3%

10.0%

1.7%

4.2%

92

22

Unplanned re-admissions in GHPW within 7 days^¶

9.9%

18.4%

30.0%

13.3%

14.2%

60

23

Unplanned re-admissions in GHPW within 30 days^¶

20.5%

26.3%

50.0%

20.0%

24.3%

71

CONTINUITY OF MENTAL HEALTH CARE

24

Patients with continuous community care

51.2%

23.4%

20.2%

25.2%

33.4%

99

25

Patients persistent with Mood stabilizers therapy

34.5%

40.6%

39.4%

38.2%

37.6%

0

26

GHPW discharges followed by any mental health outpatient contact within 14 days

61.4%

72.4%

53.3%

48.3%

60.8%

68

27

GHPW discharges followed by an outpatient psychiatric visit within 14 days

40.4%

56.6%

33.3%

30.0%

41.5%

75

28

GHPW discharges followed by home care within 14 days §

1.8%

3.3%

1.7%

1.9%

0

SAFETY OF MENTAL HEALTH CARE

29

Patients monitored for hyperglycaemia and hyperlipidaemia

(in patients treated with antipsychotics)

12.1%

13.0%

13.0%

9.7%

11.8%

0

30

Patients monitored with lithaemia

(in patients treated with Lithium)

58.8%

47.6%

50.0%

42.9%

51.1%

0

31

Patients with a complete set of clinical controls

(in patients treated with Valproic acid, Carbamazepine)

46.2%

38.8%

34.6%

21.1%

36.2%

82

32

Patients with a complete set of clinical controls

(in patients treated with Lamotrigine)

54.5%

18.8%

0%

12.5%

27.0%

25

33

Mortality (SMR), and relative 95% CI

2.47

(0.24 to 9.63)

6.56

(1.72 to 17.5)

0

0.69

(0.10 to 2.69)

1.70

(0.74 to 3.41)